Luckily, the hiring process proceeded smoothly and Charles van Zyl joined as chief executive from Belgian pharma company UCB (BE:UCB) in 2023, while Joerg Hornstein has been in post as chief finance ...
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...
Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...
Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...
Lasell University president Eric Turner is hoping that many Lasell students will find success in the real world by spending ...
A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...
Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...
AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback